| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -10,316,815 | -7,279,395 |
| Depreciation | 32,421 | 8,370 |
| Amortization expense | 472,623 | 315,082 |
| Stock-based compensation | 209,190 | 156,203 |
| Change in fair value of warrant liabilities | -115,301 | -68,431 |
| Realized foreign currency translation loss from dissolution of subsidiaries | -7,171 | -7,171 |
| Loss on asset write-off | 103,322 | 409 |
| Prepaid expenses | 535,089 | 550,785 |
| Other current assets | -109,880 | -25,103 |
| Lease liabilities | - | 0 |
| Accounts payable and accrued liabilities | 217,930 | 461,630 |
| Net cash used in operating activities | -9,814,668 | -6,924,643 |
| Payments on financed director and officer insurance | 408,969 | 292,824 |
| Proceeds from exercises of pre-funded warrants | 871 | 871 |
| Proceeds from common stock sales under atm agreement | 2,010,782 | 4,214,506 |
| Proceeds from issuance of common stock | 4,214,506 | 2,010,782 |
| Proceeds from exercises of warrants | 1,280,000 | 1,280,000 |
| Net cash provided by financing activities | 7,097,190 | 7,213,335 |
| Effect of foreign currency translation on cash | 18,301 | 5,631 |
| Net change in cash, cash equivalents, and restricted cash | -2,699,177 | 294,323 |
| Cash and cash equivalents at beginning of period | 6,922,729 | - |
| Cash and cash equivalents at end of period | 4,223,552 | - |
Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics Corp. (KTTA)